🦴 Rheumatoid Arthritis - Complete Slide-by-Slide Exam Guide

All 20 Slides | Deep Explanations | Mnemonics | 5 Viva Q&A per Slide

📌 SLIDE 1 - Title Slide: Rheumatoid Arthritis (Pathology Seminar)

Explanation

• RA is the most common autoimmune inflammatory arthritis
• Tests understanding of: immune mechanisms, autoantibodies, histopathology, and clinical features

"RA = Really Angry Autoimmunity" - the immune system attacks the synovium and eventually destroys the joint.

5 Viva Questions - Slide 1

A: Chronic systemic autoimmune inflammatory polyarthritis primarily affecting synovial joints, with potential extra-articular manifestations.

A: Robbins Pathologic Basis of Disease (Robbins-aligned).

A: No. RA is a systemic disease. It can affect lungs, heart, eyes, skin (nodules), blood vessels, and kidneys (amyloidosis).

A: Inflammatory = driven by immune-mediated inflammation (not wear-and-tear like osteoarthritis). Polyarthritis = affecting multiple joints (5 or more).

A: RA is immune-mediated (autoimmune), starts in synovium, affects small joints symmetrically, and causes systemic features. Osteoarthritis is degenerative (wear-and-tear), affects large weight-bearing joints, and has NO systemic features.

📌 SLIDE 2 - Set Induction (Clinical Case Trigger)

Explanation

• 45-year-old woman
• Morning stiffness (lasting >1 hour)
• Symmetric joint involvement
• Question: What is the diagnosis?

Breaking Down the Clues:

"SWaMP" - Stiffness (morning, >1 hr), Women (more affected), Symmetric Multiple joints, Pain

5 Viva Questions - Slide 2

A: In RA, morning stiffness lasts more than 1 hour (often several hours). In OA, it lasts less than 30 minutes.

A: During sleep/rest, synovial fluid accumulates inflammatory mediators and the inflamed synovium stiffens. Movement and heat (via the day's activity) mobilize fluid and reduce stiffness.

A: Predominantly affects women (F:M ratio = 3:1). Peak onset is between 40-60 years of age, though it can occur at any age.

A: Symmetric involvement (same joints on both sides) is a hallmark of RA and is one of the distinguishing features from other arthritides like psoriatic arthritis (asymmetric).

A: Suspect RA. Order RF, Anti-CCP antibodies, ESR, CRP, and X-rays of hands/wrists. Apply 2010 ACR/EULAR criteria to confirm.

📌 SLIDE 3 - Definition

Explanation

1. Chronic - persists for months to years; not self-limiting
2. Autoimmune - body's immune system attacks its own tissues (synovium)
3. Inflammatory - driven by cytokines (TNF-α, IL-1, IL-6), NOT degenerative
4. Polyarthritis - involves multiple joints (poly = many)
5. Synovial destruction - the primary target is the synovial membrane, which becomes a destructive "pannus" tissue

Normal synovium → Synovitis (inflammation) → Pannus formation (granulation tissue) → Cartilage & bone erosion → Joint destruction & ankylosis

"CAPS-D" - Chronic, Autoimmune, Polyarthritis, Synovial destruction, Disease that is systemic

5 Viva Questions - Slide 3

A: RA is a chronic systemic autoimmune inflammatory disease primarily affecting synovial joints, characterized by persistent synovitis, pannus formation, cartilage and bone erosion, leading to progressive joint destruction, deformity, and extra-articular manifestations.

A: The synovial membrane (synovium) is the primary target. Inflammation begins here (synovitis) and spreads to erode adjacent cartilage and bone.

A: Inflammatory arthritis features: warmth, erythema, significant swelling, prolonged morning stiffness, systemic signs (fever, elevated ESR/CRP), and inflammatory cells on synovial fluid analysis (>2000 WBC/mm3). Non-inflammatory (like OA) lacks these.

A: Systemic means the disease extends beyond the joints to affect other organs: lungs (fibrosis, nodules), heart (pericarditis), eyes (scleritis, sicca), skin (rheumatoid nodules), and blood vessels (vasculitis).

A: Pannus is a destructive layer of inflammatory granulation tissue (fibroblasts, macrophages, synovial cells) that grows over and invades the articular cartilage and bone, causing irreversible erosions.

📌 SLIDE 4 - Etiology

Explanation

1. Genetics - HLA-DR4 (Most Important)

• RA is strongly associated with HLA-DRB1*04 alleles (HLA-DR4)
• These alleles share a "shared epitope" - a conserved sequence of amino acids (positions 67-74) in the third hypervariable region of HLA-DRB1
• This shared epitope binds citrullinated peptides more avidly, triggering the autoimmune response
• ~50-60% genetic contribution to RA risk
• Key point: HLA-DR4 = most common HLA association in RA

2. Smoking

• Most well-established environmental trigger
• Smoking promotes protein citrullination in lung tissue
• Citrullinated proteins become autoantigens → trigger anti-CCP antibody formation
• Smokers with HLA-DR4 have 21x higher risk of seropositive RA

3. Female Sex

• F:M = 3:1
• Estrogen promotes Th2 immune responses and B-cell activity
• Pregnancy often causes RA remission (anti-inflammatory estrogen shift), while postpartum period triggers flares

4. Environmental Triggers

• Infections: Epstein-Barr virus, Proteus mirabilis (molecular mimicry)
• Gut microbiome dysbiosis
• Silica exposure, periodontal disease (Porphyromonas gingivalis causes citrullination)

"FHES" - Female, HLA-DR4, Environmental (smoking), Susceptibility genes

5 Viva Questions - Slide 4

A: HLA-DRB1*04 (HLA-DR4). It carries the "shared epitope" that preferentially binds citrullinated peptides and is present in ~70% of seropositive RA patients.

A: A conserved amino acid sequence at positions 67-74 of the HLA-DRB1 third hypervariable region (shared across multiple DR4, DR1 alleles) predisposes to RA by preferentially presenting citrullinated self-peptides to autoreactive T cells.

A: Smoking stimulates protein citrullination (conversion of arginine to citrulline) in the lungs. In genetically susceptible individuals (HLA-DR4), these citrullinated proteins act as autoantigens triggering anti-CCP antibodies and the autoimmune cascade.

A: Estrogen stimulates B-cell proliferation and antibody production. The hormonal fluctuations in women (especially the postpartum drop in estrogen) are associated with RA flares. Pregnancy (high estrogen) often causes remission.

A: Proteus mirabilis and Epstein-Barr virus (EBV). Their proteins share sequence homology with HLA-DR4 shared epitope or collagen, potentially triggering cross-reactive autoimmunity. Porphyromonas gingivalis (periodontal pathogen) is linked via citrullination.

📌 SLIDE 5 - Pathogenesis

Explanation

Step-by-Step Pathogenesis:

• Environmental trigger (infection/citrullinated proteins) → Processed by APCs (Antigen Presenting Cells)
• APCs (macrophages, dendritic cells) present antigen on HLA-DR4 molecules to CD4+ T cells

• CD4+ Th1 cells are the central orchestrators
• They activate macrophages and B cells
• They produce IFN-γ, TNF-α

• Synoviocytes proliferate (lining becomes multilayered, up to 10+ cell layers vs. normal 1-3)
• Pannus = proliferative granulation tissue consisting of:
  • Type A synoviocytes (macrophage-like)
  • Type B synoviocytes (fibroblast-like = FLS - Fibroblast-Like Synoviocytes)
  • T cells, B cells, plasma cells
  • New blood vessels (angiogenesis via VEGF)

• Pannus produces MMPs (Matrix Metalloproteinases) and cathepsins
• These enzymes degrade Type II collagen in cartilage
• RANKL activates osteoclasts → marginal bone erosions

• Repeated destruction → fibrous tissue replaces joint → fibrous ankylosis
• Eventually → bony ankylosis (joint completely fused)

"TACT-PAC" - Trigger → APC → CD4 T cells → TNF/cytokines → Pannus → Ankylosis → Cartilage erosion

5 Viva Questions - Slide 5

A: TNF-α (Tumor Necrosis Factor-alpha) produced by macrophages is the most important cytokine. It drives synovitis, systemic inflammation, and bone erosion. Clinically, TNF-α blockers (infliximab, etanercept, adalimumab) are the most effective biologics for RA.

A: Pannus is an aggressive proliferative granulation tissue formed by activated synoviocytes (macrophage-like and fibroblast-like), T cells, macrophages, and new blood vessels. It invades cartilage and bone, releasing MMPs and cathepsins that degrade the extracellular matrix, and expressing RANKL that activates osteoclasts to erode bone.

A: RANKL (Receptor Activator of NF-κB Ligand) is expressed by activated T cells and fibroblast-like synoviocytes at the pannus-bone interface. It binds to RANK on osteoclast precursors, activating them to resorb bone - producing the characteristic marginal erosions on X-ray.

A: Type A (macrophage-like): phagocytosis, cytokine production (TNF-α, IL-1). Type B (fibroblast-like synoviocytes/FLS): produce MMPs and collagen; they are the primary invasive cells in pannus that erode cartilage and bone.

A: Synovitis (inflammation of synovium) → Pannus formation (proliferative granulation tissue) → Cartilage erosion (MMPs) → Subchondral bone erosion (osteoclasts via RANKL) → Joint space narrowing → Fibrous ankylosis → Bony ankylosis.

📌 SLIDE 6 - Autoantibodies

Explanation

1. Rheumatoid Factor (RF)

• What it is: IgM antibody directed against the Fc portion of IgG
• Think: "An antibody attacking another antibody"
• Sensitivity: ~80% of RA patients (but NOT specific)
• Specificity: Poor - positive in many other conditions

Cirrhosis, Hep B/C, Infective endocarditis, Lupus (SLE), Leprosy, Sjogren's syndrome (and normal elderly >5%)

• RF-positive RA = Seropositive RA (worse prognosis, more extra-articular features)
• RF-negative RA = Seronegative RA (~20-25% of RA)

2. Anti-CCP (Anti-Cyclic Citrullinated Peptide)

• What it is: Antibody against citrullinated proteins (proteins where arginine is converted to citrulline by PAD enzymes)
• Sensitivity: ~70-80%
• Specificity: ~95-98% - MOST SPECIFIC test for RA
• Can be positive years before clinical RA (pre-clinical RA)
• Strongly associated with HLA-DR4 and smoking
• Also called ACPA (Anti-Citrullinated Protein Antibodies)
• High anti-CCP titer = more aggressive/erosive disease

3. ANA (Antinuclear Antibodies)

• Positive in only ~30% of RA patients (uncommon)
• Much less specific than anti-CCP
• Low titer, usually without clinical significance in RA
• Mainly positive in conditions like SLE, Sjogren's, scleroderma

"RF is Rough (80% sensitive, poor specificity); Anti-CCP is Crisp and Precise (95% specific)"

5 Viva Questions - Slide 6

A: RF is predominantly an IgM antibody directed against the Fc region (constant region) of IgG molecules. It forms immune complexes that activate complement, contributing to synovial inflammation. It is positive in ~80% of RA patients.

A: Anti-CCP (Anti-Cyclic Citrullinated Peptide) antibodies with ~95-98% specificity for RA. They detect antibodies against citrullinated proteins and can be positive years before clinical disease onset.

A: Yes. Seronegative RA (~20-25%) is negative for both RF and anti-CCP. Diagnosis relies on clinical features (synovitis, morning stiffness, symmetric joints), elevated ESR/CRP, and the 2010 ACR/EULAR criteria.

A: RF is also positive in: Sjogren's syndrome (~75%), Infective endocarditis, Hepatitis C, SLE, Primary biliary cirrhosis, and in elderly healthy individuals (>5%).

A: High anti-CCP titer predicts a more aggressive, erosive disease course. It is associated with rapid joint destruction, extra-articular manifestations, and poor functional outcomes. It helps guide early aggressive DMARD therapy.

📌 SLIDE 7 - Gross Morphology

Explanation

Gross Findings in RA (Robbins-based):

• Edematous, hyperemic, boggy synovium
• Synovial membrane becomes thickened (normally thin, delicate)
• Villous projections form from the synovial surface (papillary hypertrophy)
• The joint cavity fills with turbid, yellowish inflammatory synovial fluid

• Pannus = red/brown, tongue-like sheet of granulation tissue
• Extends from the synovial edges across the cartilage surface ("peel of orange" creeping over the cartilage)
• Gross appearance: reddish-brown vascular granulation tissue covering the articular surface

• Surface becomes irregular, fibrillated, pitted
• Erosions appear at the cartilage-pannus junction
• Eventually cartilage is completely destroyed

• Marginal erosions (juxta-articular) - visible at the cartilage-bone junction
• Subchondral bone becomes exposed as cartilage is lost
• Periarticular osteopenia (from disuse + IL-1/IL-6 effects)

• Fibrous ankylosis - fibrous tissue bridges the joint
• Bony ankylosis - complete bony fusion (more common in small joints)
• Joint deformity (swan neck, boutonniere, ulnar deviation)

"VIPER" - Villous hypertrophy, Inflamed synovium, Pannus, Erosions of bone/cartilage, Redness (hyperemia)

5 Viva Questions - Slide 7

A: The synovium becomes edematous, hyperemic, and thickened, with formation of villous (papillary) projections extending into the joint cavity. The joint is filled with turbid inflammatory fluid rich in neutrophils.

A: Pannus appears as a reddish-brown, tongue-like sheet of vascular granulation tissue that grows from the synovial edges over the articular cartilage surface. It is vascular, friable, and destructive.

A: Marginal erosions occur at the "bare area" of the joint - the part of the bone between the cartilage edge and the synovial reflection, which has no protective cartilage cover. Pannus directly invades this exposed bone, producing characteristic marginal erosions seen on X-ray.

A: Fibrous ankylosis: fibrous scar tissue bridges the joint space - joint is stiff but some mobility remains. Bony ankylosis: new bone formation across the joint completely fuses it - joint is completely immobile. Bony ankylosis is more common in RA of small joints (wrists, tarsal joints).

A: RA synovial fluid is inflammatory: turbid/yellow, decreased viscosity, WBC count 2,000-50,000/mm3 (predominantly neutrophils in acute phases), low glucose (compared to serum), elevated protein. "Rice bodies" (free-floating fragments of fibrin/necrotic tissue) may be seen.

📌 SLIDE 8 - Microscopy (Histopathology)

Explanation

Histopathological Features (Harsh Mohan + Robbins):

• Hyperplasia of synovial lining cells (intimal hyperplasia)
• Normal synovium: 1-3 cell layers
• RA synovium: up to 8-10+ cell layers (villous folds)
• Lined by plump, hypertrophied synoviocytes

• Dense infiltrate of CD4+ T lymphocytes (most numerous), B cells, plasma cells, macrophages
• Lymphoid follicles with germinal centers (like lymph nodes in the joint!)
  • Called ectopic lymphoid neogenesis / tertiary lymphoid structures
  • This is a hallmark of RA synovitis
• Plasma cells producing RF and anti-CCP locally in the joint

• Prominent new blood vessel formation (angiogenesis)
• VEGF (Vascular Endothelial Growth Factor) drives this
• New vessels feed the inflammatory tissue

• Fibrin deposits on the synovial surface
• May organize into "rice bodies" (fibrin + necrotic villi)

• Sheets of granulation tissue: fibroblasts, macrophages, new vessels, lymphocytes
• At the cartilage invasion front: MMP-expressing fibroblasts digesting type II collagen
• At the bone invasion front: osteoclasts activated by RANKL

• Chondrocytes become necrotic
• Cartilage matrix depletion (proteoglycans lost first → type II collagen degraded)
• Bone shows osteoclastic erosion

"HALF-P" - Hyperplasia (synovial lining), Angiogenesis, Lymphoid follicles with germinal centers, Fibrin deposits, Pannus (granulation tissue)

5 Viva Questions - Slide 8

A: Lymphoid follicles with germinal centers (ectopic tertiary lymphoid organs) within the inflamed synovium, along with synovial lining hyperplasia (8-10 cell layers), CD4+ T cell infiltration, and plasma cells producing RF/anti-CCP.

A: Normal synovium has 1-3 cell layers. In RA, there is marked intimal hyperplasia with 8-10+ layers of plump, activated synoviocytes (both macrophage-like Type A and fibroblast-like Type B). This creates the characteristic villous folds (papillary hypertrophy).

A: Pannus is composed of: proliferating fibroblast-like synoviocytes (FLS), macrophages, CD4+ T cells, plasma cells, and new blood vessels (angiogenesis). At the invasive front it expresses MMPs (collagenases) and RANKL.

A: RA synovium shows: prominent lining hyperplasia, dense lymphoplasmacytic infiltrate, lymphoid follicles with germinal centers, and florid pannus. OA synovium may show mild lymphocyte aggregates but they are small, without germinal centers, and lining hyperplasia is less pronounced.

A: Congo red stain - amyloid deposits (AA amyloid from serum amyloid A protein) show apple-green birefringence under polarized light. This occurs in secondary (AA) amyloidosis, a complication of chronic RA.

📌 SLIDE 9 - Clinical Manifestations

Explanation

Key Clinical Features:

• Aching, throbbing pain in affected joints
• Worse in the morning and after inactivity (inflammatory pattern)
• Relieved by activity/movement

• Soft, boggy swelling due to synovial thickening and effusion
• Warm joints (not usually hot red like gout)
• Fusiform swelling of PIP joints

• Duration correlates with disease activity

• 1 hour = inflammatory; <30 min = degenerative

"RA Attacks MCPs and PIPs, but Divorces DIPs"

• Ulnar deviation of fingers at MCPs (most classic!)
• Swan neck deformity (PIP hyperextension + DIP flexion)
• Boutonniere deformity (PIP flexion + DIP hyperextension)
• Z-thumb deformity
• Piano key sign (distal ulna subluxation)

"USB" = Ulnar deviation, Swan neck, Boutonniere

5 Viva Questions - Slide 9

A: DIP joints (Distal Interphalangeal) are classically spared in RA. The lumbar and thoracic spine are also spared (only cervical spine, particularly C1-C2/atlantoaxial joint, is affected).

A: Swan-neck deformity involves PIP joint hyperextension + DIP joint flexion. It is caused by rupture of the volar plate of the PIP joint and extensor tendon imbalance. The finger looks like a swan's neck.

A: Swan-neck = PIP hyperextension + DIP flexion. Boutonniere = PIP flexion + DIP hyperextension. Boutonniere occurs when the central slip of the extensor tendon over the PIP ruptures, causing the lateral bands to slip to the sides (like a button through a buttonhole).

A: Ulnar deviation is the lateral (ulnar-side) deviation of the fingers at the MCP joints. It results from synovitis weakening the stabilizing structures of the MCP joints, with muscles and tendons pulling the fingers toward the ulnar side. It is the most characteristic hand deformity of RA.

A: RA can involve the atlantoaxial (C1-C2) joint, causing atlantoaxial subluxation. The transverse ligament of C1 is destroyed by pannus, allowing the odontoid peg of C2 to compress the spinal cord, causing myelopathy, quadriplegia, or sudden death. Any patient with RA requires cervical spine X-rays before general anesthesia/intubation.

📌 SLIDE 10 - Extra-articular Manifestations

Explanation

Major Extra-articular Manifestations:

• Most common extra-articular feature
• Subcutaneous nodules over pressure points (olecranon, fingers, Achilles tendon, sacrum)
• Histology: central fibrinoid necrosis surrounded by palisading macrophages (epithelioid histiocytes), then a rim of lymphocytes and fibrous tissue
• Associated with high RF titers and more severe disease
• Pulmonary nodules can also occur (Caplan syndrome in miners = RA nodules + pneumoconiosis)

• Pleural effusion (most common pulmonary feature - exudative)
• Interstitial lung disease (ILD) - progressive fibrosis
• Pulmonary nodules
• Obliterative bronchiolitis
• Pulmonary hypertension

• Keratoconjunctivitis sicca (dry eyes) - secondary Sjogren's syndrome
• Scleritis (painful, potentially sight-threatening)
• Episcleritis (less severe)
• Scleromalacia perforans (painless, severe - thinning/perforation of sclera)

• Pericarditis (most common cardiac feature)
• Accelerated atherosclerosis (from chronic inflammation)
• Myocarditis
• Constrictive pericarditis

• Rheumatoid vasculitis - occurs in long-standing seropositive RA
• Affects small-medium vessels
• Features: digital infarcts, nail-fold infarcts, peripheral neuropathy, leg ulcers, visceral ischemia

"HELP VN" - Heart (pericarditis), Eye (scleritis, sicca), Lung (ILD, effusion), Peripheral neuropathy/Pulmonary, Vasculitis, Nodules (subcutaneous)

5 Viva Questions - Slide 10

A: Rheumatoid nodule shows: central zone of fibrinoid necrosis, surrounded by a layer of palisading macrophages (epithelioid histiocytes) arranged radially, further surrounded by lymphocytes, plasma cells, and a fibrous capsule. This is called palisading granuloma (though it is necrobiotic, not true caseating granuloma).

A: Caplan syndrome (rheumatoid pneumoconiosis) is the combination of RA + pulmonary pneumoconiosis (coal dust, silica exposure) resulting in large well-defined pulmonary nodules (0.5-5 cm) superimposed on the background of pneumoconiosis. The nodules are histologically similar to rheumatoid nodules.

A: Pleural effusion (exudative, with low glucose and low complement). However, interstitial lung disease (ILD) is the most clinically serious pulmonary complication.

A: Scleromalacia perforans - progressive, painless thinning and perforation of the sclera - can lead to loss of intraocular contents and blindness. Scleritis is also serious and causes pain/vision loss. Secondary Sjogren's (dry eyes) is most common but less vision-threatening.

A: Chronic systemic inflammation (elevated TNF-α, IL-6, CRP) accelerates atherosclerosis via endothelial dysfunction, oxidative stress, and dyslipidemia. RA patients have 1.5-2x higher risk of myocardial infarction compared to the general population. Pericarditis, myocarditis, and valvular disease also contribute.

📌 SLIDE 11 - Laboratory Features

Explanation

Key Lab Tests:

• Positive in ~80% of RA (seropositive RA)
• IgM anti-IgG antibody
• NOT specific - positive in many other conditions
• Titers correlate with disease activity and extra-articular features

• Can precede clinical symptoms by 5-10 years
• Predicts erosive, aggressive disease
• Used for early diagnosis and risk stratification

• ESR (Erythrocyte Sedimentation Rate): Non-specific marker of inflammation; correlates with disease activity
• CRP (C-Reactive Protein): More sensitive and faster to rise/fall than ESR; direct response to IL-6
• Both useful to monitor disease activity (DAS28 score uses ESR or CRP)

• Common in active RA
• Caused by: IL-6 → hepcidin production → reduced iron release from stores → functional iron deficiency
• Normal MCV (normocytic), normal MCH, low serum iron, normal/elevated ferritin
• This is NOT iron deficiency anemia - distinguish by elevated ferritin (storage iron is trapped)

• Thrombocytosis (elevated platelets - reactive)
• ↑ Acute phase proteins (fibrinogen, serum amyloid A)
• ↑ Alkaline phosphatase (ALP) - from bone involvement
• Synovial fluid: WBC 5,000-50,000 cells/mm3 (predominantly neutrophils)

"RACE" - RF positive, Anti-CCP (most specific), CRP/ESR elevated, ESR + normocytic anemia

5 Viva Questions - Slide 11

A: CRP rises and falls faster (within hours) in response to IL-6 stimulation - better for acute monitoring. ESR is slower to change, affected by many factors (fibrinogen, albumin, red cell morphology), and more useful for long-term monitoring. DAS28 uses ESR. CRP is the better acute-phase marker.

A: In RA, IL-6 stimulates hepatic production of hepcidin, which blocks ferroportin on macrophages and enterocytes, trapping iron in storage cells. This results in low serum iron, elevated ferritin, normal MCV - a normocytic normochromic anemia despite adequate iron stores.

A: Anti-CCP has ~95-98% specificity vs. RF's ~80% sensitivity but poor specificity. Anti-CCP can be positive years before symptoms (useful for early/pre-clinical diagnosis), and a high titer predicts aggressive erosive disease, helping guide treatment intensity.

A: Inflammatory synovial fluid: turbid, low viscosity, WBC 5,000-50,000/mm3 (predominantly neutrophils in active RA), decreased glucose (<50% serum), elevated protein, decreased complement (C3/C4 consumed by immune complexes), negative culture (sterile).

A: This is Anemia of Chronic Disease (ACD) in RA. The elevated ferritin (stored iron) with low serum iron distinguishes it from iron deficiency anemia. Treatment focuses on controlling RA disease activity (DMARDs, biologics) - when inflammation is controlled, anemia improves. Iron supplementation alone is ineffective unless concurrent iron deficiency is proven.

📌 SLIDE 12 - Radiological Features

Explanation

X-ray Findings in RA (in order of appearance):

• Soft tissue swelling around joints (periarticular edema)
• Periarticular osteopenia (juxta-articular osteoporosis around the joint)
  • Due to: hyperemia, disuse, IL-1/IL-6 stimulating osteoclasts locally

• Joint space narrowing - due to cartilage destruction
• Uniform/concentric narrowing (in all parts of the joint, unlike OA where it is asymmetric)

• Marginal erosions at the "bare area" of the joint
• These appear as punched-out defects or notching at the cartilage-bone junction
• MOST SPECIFIC radiological finding for RA
• First appear at: 2nd and 3rd MCP joints, ulnar styloid, radial side of 1st MCP, MTP joints

• Subluxation and dislocation of joints
• Deformities visible on X-ray (ulnar deviation, boutonniere, swan-neck)
• Bony ankylosis (complete fusion, carpals commonly)
• Atlantoaxial subluxation on lateral C-spine X-ray

"SOME-J" - Soft tissue swelling, Osteopenia (periarticular), Marginal erosions, Erosions advance, Joint space narrows → deformity

5 Viva Questions - Slide 12

A: Marginal erosions at the "bare area" of the joint (the zone between articular cartilage edge and synovial reflection, lacking cartilage protection). These appear as punched-out defects on X-ray, most commonly first seen at the 2nd/3rd MCP joints and ulnar styloid.

A: Periarticular osteopenia is localized bone density loss around the inflamed joint. It occurs due to: local hyperemia (increases bone resorption), disuse atrophy, and pro-inflammatory cytokines (IL-1, IL-6, TNF-α, RANKL) stimulating local osteoclast activity.

A: In RA, joint space narrowing is concentric/uniform (affects all parts of the joint space equally due to global synovitis and cartilage loss). In OA, narrowing is asymmetric/focal (affects only the most weight-bearing part first, usually medial compartment of knee).

A: Atlantoaxial subluxation on lateral cervical spine X-ray (atlantodens interval >3 mm in adults, >5 mm in children). This indicates C1-C2 instability from transverse ligament destruction by RA. All RA patients must have cervical spine X-rays before intubation/anesthesia to avoid spinal cord injury.

A: MRI can detect bone marrow edema (which precedes erosions), early synovitis, tendinopathy, and very small erosions months to years before they appear on plain X-ray. Early detection allows earlier aggressive treatment to prevent irreversible joint damage.

📌 SLIDE 13 - 2010 ACR/EULAR Classification Criteria

Explanation

The 4 Domains + Scoring Table:

Key Points:

• Requires at least 1 joint with definite synovitis NOT explained by another disease
• Seronegative RA (negative RF + ACPA, score 0 for serology) can still score ≥6 with many joints + elevated ESR + long duration
• Rheumatoid nodules and X-ray erosions are NOT part of the 2010 criteria (they occur late, not early)
• The 2010 criteria are classification criteria (not diagnostic) - aimed at identifying patients with early RA likely to develop chronic erosive disease

"JSAD" - Joints, Serology, Acute phase reactants, Duration

5 Viva Questions - Slide 13

A: A score of ≥6 out of 10 fulfills requirements for definite RA classification, provided the patient has at least one joint with definite clinical synovitis not explained by another disease.

A: Joints 4-10 small joints = 3, High-positive RF = 3, Abnormal CRP = 1, Duration ≥6 weeks (3 months) = 1. Total = 3+3+1+1 = 8. Score ≥6 → definite RA.

A: They occur only in late/established RA, not early disease. The 2010 criteria were designed to identify patients with early RA to enable prompt treatment and prevent irreversible joint damage.

A: Classification criteria define a homogeneous group of patients for research purposes (clinical trials, epidemiology). Diagnostic criteria are used in individual clinical practice to diagnose a specific patient. A physician can diagnose RA clinically even if classification criteria are not met.

A: Maximum = 5 (joints) + 0 (seronegative) + 1 (acute phase) + 1 (duration) = 7. Still sufficient to classify as definite RA (≥6), especially with widespread small joint involvement.

📌 SLIDE 14 - Complications

Explanation

Major Complications:

• Ulnar deviation, swan-neck, boutonniere, Z-thumb
• Caused by: tendon rupture, ligamentous laxity from pannus, muscle imbalance
• Progressive disability in untreated disease

• Fibrous ankylosis → bony ankylosis
• Most common in wrists, carpal bones, cervical spine
• Atlantoaxial subluxation (C1-C2) → risk of quadriplegia/sudden death

• Occurs in long-standing, poorly controlled RA (usually >10 years)
• Type: AA amyloidosis - serum amyloid A (SAA) protein (acute phase reactant made by liver in response to IL-6) accumulates as amyloid fibrils in tissues
• Organs affected: kidneys (proteinuria, nephrotic syndrome, renal failure), liver, spleen
• Diagnosis: Congo red staining → apple-green birefringence under polarized light
• This is a major cause of death in long-standing RA

• From: RA itself (immune dysregulation), immunosuppressive drugs (DMARDs, biologics, steroids)
• Pneumonia, septic arthritis, opportunistic infections (TB reactivation with anti-TNF)
• Septic arthritis is hard to distinguish from RA flare - joint aspiration is essential

• Accelerated atherosclerosis - leading cause of death in RA

• Steroids: osteoporosis, avascular necrosis, diabetes, infections
• Methotrexate: hepatotoxicity, pulmonary toxicity, bone marrow suppression
• Anti-TNF: TB reactivation, opportunistic infections, demyelination

"DIAVA" - Deformities, Infections (increased), Amyloidosis (AA), Vascular (atherosclerosis), Ankylosis

5 Viva Questions - Slide 14

A: Secondary (AA) amyloidosis. The protein is Serum Amyloid A (SAA), an acute-phase reactant produced chronically in RA. The kidneys are most affected (nephrotic syndrome, renal failure is the most common cause of amyloid-related death). Diagnosis: Congo red stain → apple-green birefringence under polarized light.

A: TNF-α is essential for granuloma formation - the mechanism by which the immune system contains latent TB. Anti-TNF therapy (infliximab, etanercept, adalimumab) disrupts granuloma integrity, causing reactivation of latent TB. All patients must be screened with TST/IGRA before starting anti-TNF therapy.

A: AA amyloidosis (secondary amyloidosis). Confirm with renal biopsy showing Congo red positive deposits with apple-green birefringence under polarized light, and immunohistochemistry staining positive for AA amyloid protein.

A: RA pannus destroys the transverse ligament of C1, which normally prevents the odontoid process (dens) of C2 from moving into the spinal canal. Subluxation allows the dens to compress the spinal cord and brainstem - can cause quadriplegia or sudden death (especially with neck flexion under anesthesia).

A: Felty syndrome is a triad of: RA + Splenomegaly + Neutropenia. It occurs in long-standing seropositive RA, is associated with high RF, and the neutropenia leads to recurrent serious bacterial infections. It may progress to large granular lymphocyte (LGL) leukemia.

📌 SLIDE 15 - Mnemonic Slide

Explanation

RAIN Mnemonic - Expanded:

Additional Mnemonics Collection:

Trigger → APC → CD4 T cells → TNF/cytokines → Pannus → Ankylosis → Cartilage erosion

Female, HLA-DR4, Environmental (smoking), Susceptibility genes

Soft tissue swelling, Osteopenia, Marginal erosions, Erosions advance, Joint space narrowing

Heart, Eye, Lung, Peripheral neuropathy, Vasculitis, Nodules

Deformities, Infection, Amyloidosis, Vascular, Ankylosis

Ulnar deviation, Swan neck, Boutonniere

Hyperplasia, Angiogenesis, Lymphoid follicles, Fibrin, Pannus

Joints, Serology, Acute phase reactants, Duration

5 Viva Questions - Slide 15

A: R = RF (IgM anti-IgG, 80% sensitive, poor specificity); A = Anti-CCP (95% specific, can precede clinical disease by years); I = Inflammation (TNF-α/IL-1/IL-6 driven synovitis causing morning stiffness, pannus, erosion); N = Nodules (subcutaneous fibrinoid necrosis with palisading macrophages over pressure points, indicating severe seropositive RA).

A: Ulnar deviation (MCPs), Swan-neck deformity (PIP hyperextension + DIP flexion), Boutonniere deformity (PIP flexion + DIP hyperextension). These are the three classic hand deformities of RA.

A: Joints (up to 5 pts for >10 small joints), Serology (up to 3 pts for high-positive RF/ACPA), Acute-phase reactants (1 pt for abnormal CRP/ESR), Duration (1 pt for ≥6 weeks). Score ≥6/10 = definite RA.

A: FHES covers the 4 main risk factors the examiner will ask about: Female sex (hormonal), HLA-DR4 (genetic - shared epitope), Environmental triggers (smoking - citrullination in lungs), Susceptibility genes (additional MHC and non-MHC genes like PTPN22, CTLA4).

A: Rheumatoid nodules indicate high RF titers, seropositive RA, and more severe systemic disease. Their presence correlates with more erosive joint disease, higher risk of vasculitis, pulmonary complications, and Felty syndrome. Paradoxically, methotrexate can cause "accelerated nodulosis" (more nodules despite better disease control).

📌 SLIDE 16 - Case Scenario

Explanation

Applying the JSAD Criteria:

• Joints: >10 small joints (bilateral wrists, MCPs, PIPs) = 5 points
• Serology: High-positive RF + Anti-CCP = 3 points
• Acute phase: Elevated CRP = 1 point
• Duration: 4 months (≥6 weeks) = 1 point
• Total = 10/10 → Definite RA

Clue Analysis:

5 Viva Questions - Slide 16

A: Anti-CCP antibodies (most specific), combined with RF. Apply 2010 ACR/EULAR criteria scoring. Also order ESR, CRP for baseline disease activity, and X-rays of hands/wrists for marginal erosions.

A: Symmetric, bilateral involvement of MCPs, PIPs, and wrists is a hallmark of RA and helps distinguish it from other arthritides (psoriatic = asymmetric, gout = often asymmetric, OA = DIP joints predominantly).

A: Smoking promotes protein citrullination in lung tissue. In a genetically susceptible person (HLA-DR4), these citrullinated proteins trigger anti-CCP antibody formation and T-cell activation years before clinical joint disease appears.

A: High-positive anti-CCP (>3x ULN) predicts an aggressive, erosive disease with rapid joint damage, higher risk of extra-articular manifestations (nodules, ILD, vasculitis), and worse long-term functional outcomes. She needs early aggressive DMARD therapy.

A: Treat to target: Start Methotrexate (MTX) as the anchor DMARD (first-line). Add folic acid to reduce MTX side effects. NSAIDs/short-course corticosteroids as bridging therapy for pain. Reassess DAS28 at 3-6 months; if inadequate response, add biological (anti-TNF) therapy.

📌 SLIDE 17 - Case Questions (Discussion Questions)

Explanation

Rheumatoid Arthritis - based on the classic clinical triad of symmetric inflammatory polyarthritis of small joints, morning stiffness >1 hour, and positive RF/Anti-CCP.

Anti-CCP antibodies (Anti-Cyclic Citrullinated Peptide / ACPA) - ~95-98% specific, can detect RA years before onset, predicts aggressive/erosive disease.

Multiple: AA amyloidosis (long-term), atlantoaxial subluxation (neurological emergency), accelerated atherosclerosis (leading cause of death), infection (from disease + drugs), ILD (pulmonary fibrosis).

5 Viva Questions - Slide 17

A: Anti-CCP (Anti-Cyclic Citrullinated Peptide antibodies / ACPA). Specificity ~95-98% vs. RF's poor specificity. It can be positive 5-10 years before clinical symptoms, making it ideal for early/pre-clinical diagnosis. It also predicts disease severity.

A: Seronegative RA (~20-25% of RA). Diagnosis based on clinical features (synovitis, morning stiffness, symmetric joints), elevated ESR/CRP, and ACR/EULAR score ≥6. Treat with DMARDs same as seropositive RA, though prognosis may be somewhat better.

A: Atlantoaxial subluxation with spinal cord compression - presenting as progressive weakness, hand tingling, or L'Hermitte's sign (electric shock sensation down the spine on neck flexion). Requires urgent MRI, neurosurgical evaluation, and cervical stabilization. Also: septic arthritis superimposed on RA joint.

A: Septic arthritis: typically monoarthritis (usually one joint), high fever, systemic toxicity, WBC very high, synovial fluid WBC >50,000/mm3 with >90% neutrophils, Gram stain/culture positive. RA flare: often polyarthritis, milder fever if any, synovial fluid WBC lower, sterile. Joint aspiration with culture is mandatory.

A: 1. Methotrexate (MTX): Hepatotoxicity, pulmonary toxicity, bone marrow suppression, teratogenicity (folic acid supplementation required). 2. Hydroxychloroquine: Retinal toxicity (requires annual ophthalmology review). 3. Sulfasalazine: Hepatotoxicity, skin rash, G6PD hemolysis, oligospermia.

📌 SLIDE 18 - Key Takeaways

Explanation

1. Early Diagnosis

• "Time is cartilage" - every week of uncontrolled inflammation destroys irreplaceable cartilage and bone
• Anti-CCP positivity before symptoms = opportunity for prevention
• The 2010 ACR/EULAR criteria enable early classification
• Target: treat within 3 months of symptom onset for best outcomes

2. DMARDs (Disease-Modifying Anti-Rheumatic Drugs)

• These are the cornerstone of RA treatment - they modify the disease course, not just symptoms
• First-line: Methotrexate (MTX) - the "anchor DMARD"
• If inadequate response: Biologic DMARDs (bDMARDs):
  • Anti-TNF: infliximab, etanercept, adalimumab
  • Anti-IL-6: tocilizumab
  • Anti-CD20: rituximab (B-cell depletion)
  • CTLA4-Ig: abatacept (T-cell costimulation blocker)
• Newest: JAK inhibitors (tofacitinib, baricitinib) - targeted synthetic DMARDs
• NSAIDs and steroids are adjunctive only (symptom relief, bridging) - they do NOT stop disease progression

3. Prevent Disability

• "Treat to Target (T2T)" strategy: aim for remission or low disease activity (DAS28 <2.6)
• Physical therapy, occupational therapy, joint protection
• Surgery (synovectomy, joint replacement) for advanced disease
• Prevent amyloidosis, cardiovascular disease, osteoporosis

"EDP" - Early diagnosis, DMARDs, Prevent disability

5 Viva Questions - Slide 18

A: DMARD = Disease-Modifying Anti-Rheumatic Drug. Unlike NSAIDs and steroids (which only reduce symptoms/inflammation temporarily), DMARDs alter the underlying disease course - they reduce erosion progression, prevent deformity, reduce extra-articular features, and can achieve remission. Examples: methotrexate, hydroxychloroquine, sulfasalazine, leflunomide.

A: MTX is the most effective, well-tolerated, and evidence-based conventional DMARD for RA. It works by inhibiting dihydrofolate reductase → impairs rapidly dividing immune cells, reduces inflammation. It is used as the baseline to which other DMARDs (HCQ, SSZ) or biologics (anti-TNF) are added. Folic acid 1-5 mg/day is given to reduce GI and mucosal side effects.

A: Anti-TNF agents (infliximab = chimeric monoclonal antibody; etanercept = soluble TNF receptor fusion protein; adalimumab = fully human mAb) neutralize TNF-α, preventing it from binding its receptors. This blocks the central inflammatory cascade in RA (synovitis, osteoclast activation via RANKL, systemic inflammation).

A: T2T is the recommended management strategy where: treatment is adjusted (escalated/de-escalated) frequently (every 1-3 months) to achieve a specific measurable target - remission (DAS28 <2.6) or low disease activity (DAS28 <3.2). DAS28 uses 28 joint counts, ESR/CRP, and patient global assessment. T2T significantly reduces erosion and disability compared to symptom-driven treatment.

A: 1. Physiotherapy: joint range-of-motion exercises, strengthening, aerobic conditioning. 2. Occupational therapy: joint protection techniques, assistive devices, splinting (wrist splints to prevent deformity). 3. Smoking cessation: most important modifiable risk factor. 4. Cardiovascular risk reduction: statins, BP control. 5. Osteoporosis prevention: calcium, vitamin D, DEXA scans (especially for steroid users).

📌 SLIDE 19 - MCQs

Explanation

Best answer: IgM antibody against the Fc portion of IgG, positive in ~80% of RA

Best answer: Most specific test for RA (~95-98%), can precede symptoms by years, targets citrullinated proteins

Best answer: Marginal (juxta-articular) erosions - most specific. Also: periarticular osteopenia, joint space narrowing, subluxation.

5 Viva Questions - Slide 19

A: (D) Osteophytes - Osteophytes are a feature of osteoarthritis (degenerative, bony outgrowths). RA shows marginal erosions, periarticular osteopenia, and joint space narrowing.

A: (D) Anti-CCP - ~95-98% specific for RA. ANA is seen in SLE primarily. Anti-dsDNA is specific for SLE. RF is sensitive (~80%) but not specific.

A: (B) AA amyloidosis - secondary amyloidosis is a classic complication of long-standing RA from chronic elevation of serum amyloid A. Confirm with Congo red stain on kidney biopsy.

A: (B) Lymphoid follicles with germinal centers (ectopic tertiary lymphoid neogenesis) in the inflamed synovium, along with synovial lining hyperplasia - hallmarks of RA synovitis.

A: (B) Lasts >1 hour - Inflammatory morning stiffness in RA typically lasts 1-several hours, is RELIEVED (not worsened) by activity and warmth, and WORSENS with rest. OA stiffness lasts <30 min and is worsened by prolonged activity.

📌 SLIDE 20 - Thank You / Questions

Summary & Rapid Revision Points

1. RA = chronic systemic autoimmune inflammatory polyarthritis
2. F:M = 3:1; peak age 40-60 years
3. HLA association: HLA-DR4 (shared epitope)
4. Strongest environmental trigger: smoking (via citrullination)
5. Primary target: synovial membrane (synovitis → pannus)
6. Most important cytokine: TNF-α
7. Pannus = macrophage + fibroblast + T cells + new vessels → destroys cartilage/bone via MMPs and RANKL
8. Most sensitive autoantibody: RF (~80%)
9. Most specific autoantibody: Anti-CCP (~95-98%)
10. Joints involved: MCPs, PIPs, wrists, MTPs; DIPs SPARED
11. Most classic deformity: Ulnar deviation of fingers
12. Morning stiffness: >1 hour (inflammatory)
13. Histology hallmark: lymphoid follicles with germinal centers in synovium
14. Gross pathology hallmark: pannus formation
15. X-ray hallmark: marginal erosions + periarticular osteopenia
16. ACR/EULAR 2010 criteria: score ≥6/10 = definite RA
17. Most common extra-articular: rheumatoid nodules (fibrinoid necrosis + palisading macrophages)
18. Dangerous complication: atlantoaxial subluxation (C1-C2)
19. Long-term complication: AA amyloidosis (kidneys - Congo red positive)
20. First-line treatment: Methotrexate (DMARD)

5 Final Viva Questions - Slide 20

A: Rheumatoid Arthritis is a chronic systemic autoimmune inflammatory disease primarily targeting synovial joints. It predominantly affects middle-aged women with a 3:1 female predominance. Pathogenetically, environmental triggers (especially smoking) in genetically susceptible individuals (HLA-DR4 shared epitope) lead to protein citrullination, triggering CD4+ T cell activation, cytokine storm (TNF-α, IL-1, IL-6), synovial hyperplasia, and pannus formation - a destructive granulation tissue that erodes cartilage and bone via MMPs and RANKL-mediated osteoclast activation. Autoantibodies RF (80% sensitive) and anti-CCP (95% specific) are hallmarks. Clinically: symmetric small joint polyarthritis, morning stiffness >1 hour, ulnar deviation, with extra-articular features (nodules, ILD, pericarditis, vasculitis). Diagnosed by 2010 ACR/EULAR criteria (≥6/10). Treated with DMARDs (methotrexate first-line) aiming for remission using a Treat-to-Target strategy.

A: Pre-clinical RA is the phase where anti-CCP antibodies and RF are detectable in blood (sometimes 5-10 years before joint symptoms appear) without clinical arthritis. This phase involves citrullinated protein immune responses (triggered by smoking/periodontal infection) in HLA-DR4 individuals. Identifying this stage allows: screening high-risk individuals, preventive interventions (smoking cessation, periodontal treatment), and potentially early therapeutic intervention to prevent full clinical RA.

A: 1. RA often improves during pregnancy (high estrogen is anti-inflammatory, and immunological tolerance to fetal antigens suppresses inflammation). 2. Post-partum flares are common (estrogen drops). 3. Methotrexate must be stopped 3-6 months before conception (highly teratogenic). 4. Hydroxychloroquine is relatively safe in pregnancy. 5. Low-dose steroids can be used if necessary. 6. Anti-TNF agents: generally stopped by 2nd-3rd trimester (except certolizumab - minimal placental transfer). 7. RA patients have slightly higher risk of: preterm birth, low birth weight, cesarean section.

A: The "window of opportunity" is the early phase of RA (first few weeks to months of symptoms) when the immune response is still modifiable and joint damage is minimal. Aggressive DMARD therapy within this window can achieve drug-free remission in some patients, prevents irreversible erosion, and significantly improves long-term outcomes. After this window closes (once structural damage sets in), treatment can only slow progression, not reverse it. This is why early diagnosis and treatment are so critical.

🎯 Master Mnemonic Summary